Key Highlights

  • Total company revenues reached $524.4 million in Q3 2026, up 268% year-over-year, driven largely by BRINSUPRI commercial ramp.
  • BRINSUPRI revenues of $400.1 million grew 29% sequentially from Q2 2026, reflecting accelerating U.S. market momentum.
  • ARIKAYCE revenues of $124.4 million grew 9% year-over-year, supported by 21% growth in international markets.
  • Insmed raised its full-year 2026 BRINSUPRI Revenue guidance to $1.35–$1.4 billion and ARIKAYCE guidance to $460–$470 million.

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company, reported total revenues of $524.4 million for the third quarter of 2026, a period defined by accelerating commercial momentum behind BRINSUPRI — its treatment for non-cystic fibrosis bronchiectasis — and continued growth from the established ARIKAYCE franchise. The quarter's performance prompted the company to raise the lower end of its full-year guidance for both major commercial products, while also marking regulatory and pipeline milestones including BRINSUPRI's approval and launch in Japan.

BRINSUPRI Sustains Rapid Commercial Trajectory

BRINSUPRI generated revenues of $400.1 million in Q3 2026, a 29% increase over the $310 million recorded in Q2 2026 and a dramatic expansion from $28.1 million in Q3 2025, when the product was in its earliest commercial phase. U.S. revenues of $398.1 million drove the bulk of performance, while international revenues of $2.0 million reflected early-stage expansion including the product's August 2026 approval and October 2026 launch in Japan by the Ministry of Health, Labour and Welfare — marking BRINSUPRI as the first and only approved treatment for non-cystic fibrosis bronchiectasis in that market.

For the nine months ended September 30, 2026, BRINSUPRI revenues totaled $917.1 million, reflecting the product's rapid uptake since its 2025 U.S. approval. Insmed raised its full-year 2026 BRINSUPRI revenue guidance to a range of $1.35 billion to $1.4 billion.

ARIKAYCE Delivers Steady Growth While Regulatory Milestone Approaches

ARIKAYCE, Insmed's treatment for refractory Mycobacterium avium complex lung disease, generated revenues of $124.4 million in Q3 2026, up 9% from $114.3 million in Q3 2025. International markets were a key growth contributor, with international ARIKAYCE revenues increasing 21% year-over-year to $48.9 million. U.S. revenues grew modestly to $75.5 million from $74.0 million a year earlier.

In September 2026, the FDA accepted Insmed's supplemental New Drug Application for ARIKAYCE as a treatment for MAC lung disease — including for newly diagnosed patients or those facing recurrent infections — and granted Priority Review with a PDUFA action date of January 28, 2027. Insmed also plans to submit Phase 3 ENCORE study data to Japan's Pharmaceuticals and Medical Devices Agency in Q4 2026 to support a potential label expansion in that market. The company raised its full-year 2026 ARIKAYCE revenue guidance to $460–$470 million.

Pipeline Advances Across Multiple Indications

Insmed reported several clinical developments during the quarter. In its TPIP program, the company has enrolled more than 35% of patients in the Phase 3 PALM-ILD study in pulmonary hypertension associated with interstitial lung disease, with full enrollment expected in the first half of 2028. In July 2026, the first patient was enrolled in the Phase 3 PALM-PAH study targeting pulmonary arterial hypertension, and in September 2026 the Phase 3 PALM-PPF study in progressive pulmonary fibrosis was initiated.

On the financial side, Insmed reported a net loss of $100.3 million, or $0.46 per share, in Q3 2026, compared to a net loss of $370.0 million, or $1.75 per share, in Q3 2025. The narrowing loss reflects higher revenues partially offset by increased R&D expenses of $270 million and SG&A expenses of $253 million as the company continued to invest in BRINSUPRI's commercial build and pipeline expansion.

Insmed's third-quarter results reflect a company executing on two fronts simultaneously: converting BRINSUPRI's early U.S. commercial momentum into sustained revenue at scale while continuing to invest in a pipeline spanning multiple respiratory and rare disease indications. With raised guidance for both products and a broad clinical program advancing, the company enters Q4 2026 with visible near-term revenue drivers and a set of regulatory catalysts that extend into 2027.